Third Annual
Huntington Disease Clinical Research Symposium
Organized by the Huntington Study Group
Saturday, November 21, 2009
8:00a.m. - 1:30p.m.
Hyatt Regency
Baltimore, MD 21202 U.S.A.
To be held on Saturday, November 21, 2009 at the Hyatt Regency
in Baltimore, Maryland, USA.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Rochester School of Medicine and Dentistry designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Symposium consists of four keynote speakers and four platform presentations by the following individuals with allotted time for questions and answers after each presenter.
|
8:00 am – 9:00 am
|
Poster Setup & Viewing, Continental Breakfast
|
|
9:00 am – 9:10 am
|
Introduction (Jang-Ho Cha, MD, PhD, Symposium Chair; Richard Dubinksy, MD, Symposium co-Chair)
|
|
9:10 am – 9:50 am
|
Keynote Presentation I
Judy Roberson, RN, President, HDSA Northern California Chapter
"Huntington's Advocacy: Why I Care"
|
|
|
|
|
9:50 am – 10:05 am
|
Ferdinando Squitieri, MD, PhD, IRCCS Neuromed, Italy
"Early Defect of Transforming Growth Factor β-1 Formation in Huntington's Disease"
|
|
|
|
|
10:05 am – 10:20 am
|
Platform Presentation II
Ashwini Rao, EdD, OTR, Columbia University
"Impairments in Precision Grip Control in Pre-Symptomatic Huntington's Disease"
|
|
|
|
|
10:20 am – 11:30 am
|
Poster Viewing (Snack & Beverage Available)
|
|
|
|
|
11:30 am – 12:10 pm
|
Keynote Presentation II
Jan Nolta, PhD, University of California, Davis
"Working Toward Mesenchymal Stem Cell-Mediated Therapies for HD"
|
|
|
|
|
12:10 pm – 12:25 pm
|
Platform Presentation III
Karen Anderson, MD, University of Maryland
"Early vs. Late Huntington's Disease- Is There a Difference in Psychiatric Symptom Severity?"
|
|
|
|
|
12:25 pm – 12:40 pm
|
Platform Presentation IV
Douglas Langbehn, MD, PhD, University of Iowa
"Multivariate Clinical Predictors of Huntington Disease (HD): Prospective Results from the PREDICT-HD Study"
|
|
|
|
|
12:40 pm – 1:20 pm
|
Keynote Presentation III
Celia Witten, PhD, MD, Center for Biologics Evaluation and Research, Food and Drug Administration
"FDA Regulation of Stem Cell Therapy"
|
|
|
|
|
1:20 pm
|
Adjourn
|
POSTER SESSION
Posters will be staffed from 8:00 – 9:00 AM and 10:20 – 11:30 AM in the Constellation Ballroom.
Poster 1
Caregiver Quality of Life in Huntington’s Disease.
M. Cox,1 A. Feigin,2 and B. Napolitano.3 1North Shore-Long Island Jewish Health System, New Hyde Park, NY, USA, 2The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA, and 3Barbara Napolitano, MA, Biostatistics Unit, Feinstein Institute for Medical Research, Manhasset, NY, USA.
Poster 2
Genetic Discrimination of Individuals at Risk of Huntington's Disease: Further Analysis of the RESPOND-HD Data from Australia (Site 144).
A. Goh,1,2 O. Yastrubetskaya,1,2 and E. Chiu.1,2 1Academic Unit for The Psychiatry of Old Age, The University of Melbourne, Victoria, Australia and 2St Vincent’s Aged Psychiatry Service, Melbourne, Victoria, Australia.
Poster 3
Frequency of Epileptic Seizures in a Population of Juvenile Huntington’s Disease Patients.
L. Cloud, S. Helmers, R. Jones, S. Factor, and C. Testa. Emory University School of Medicine, Atlanta, GA, USA.
Poster 4
The Effect of Video Game-Based Exercise on Dynamic Balance and Mobility in Individuals with Huntington’s Disease.
D. Kegelmeyer, S. Kostyk, N. Fritz, and A. Kloos. The Ohio State University, Columbus, OH, USA.
Poster 5
Usefulness of Two Brief Cognitive Screening Measures in Huntington’s Disease.
S. Lessig, J. Goldstein, and J. Corey-Bloom. University of California, San Diego, San Diego, CA, USA.
Poster 6
Cerebral Spinal Fluid (CSF) Volume is the Main Marker of Huntington Disease Progression Severity and Age at Onset Prediction.
F. Squitieri,1 M. Cannella,1 M. Simonelli,1 T. Martino,1 C. Colonnese,1 and A.Ciarmiello.2 1IRCCS Neuromed, Pozzilli (IS), Italy and 2Sant’Andrea Hospital, La Spezia, Italy.
Poster 7
Early Defect of Transforming Growth Factor β-1 Formation in Huntington’s Disease.
G. Battaglia,1 M. Cannella,1 B. Riozzi,1 S. Orobello,1 M. L. Maat-Schieman,2 E. Aronica,3 C. Letizia Busceti,1 A. Ciarmiello,4S. Alberti,1 J. Sassone,5 S. Sipione,6 V. Bruno,1,7 L.Frati,7 F. Nicoletti,1,7 and F. Squitieri.1 1IRCCS Neuromed,Pozzilli (IS),Italy, 2Leiden University Medical Center, Leiden, The Netherlands,3University of Amsterdam, Amsterdam, The Netherlands, 4Sant’Andrea Hospital, La Spezia,Italy,5Dino Ferrari Center, IRCCS Istituto Auxologico Italiano, Milan, Italy, 6University of Alberta, Edmonton, Canada, and 7University “Sapienza,” Rome, Italy.
Poster 8
Reliability of the Problem Behaviours Assessment for HD (short version) – Data from the TRACK-HD Study.
J. Callaghan,¹ N. Arran,¹ M.F. Boisse,6 A. Coleman,³ R. Dar Santos,³ E. Dumas,² E. 't Hart,² D. Justo,5 J. Read,4 M. Say,4 S. Van Den Bogaard,² A. Durr,5 B. Leavitt,³ R. Roos,² S. Tabrizi,4 C. Bourdet,6 E. van Duijn,² D. Craufurd,¹ and the TRACK-HD Investigators. 1Department of Genetic Medicine, Central Manchester University Hospitals Foundation NHS Trust and University of Manchester, Manchester, UK, ²Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands, ³Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada, 4Institute of Neurology, University College London, London, UK, 5Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, 75013 Paris, France, and 6 Service de Neurologie, CHU Henri Mondor-Albert Chenevier, AP-HP, Unité Inserm 955, Equipe 1, Institut Mondor de Recherche Biomédicale, Créteil, France.
Poster 9
The Short Version of the Problem Behaviours Assessment for HD (PBA-s): An Item Response Analysis Using Data from the TRACK-HD Study.
K. Evans,¹ A. Vaccarino,¹ D. Craufurd,² J. Callaghan,² A. Durr,³ B. Leavitt,4 R. Roos,5 S. Tabrizi,6 and the TRACK-HD Investigators. ¹Ontario Cancer Biomarker Network, Toronto, Ontario, Canada, ²Department of Genetic Medicine, Central Manchester University Hospitals Foundation NHS Trust and University of Manchester, Manchester, UK, ³Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, 75013 Paris, France, 4Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada, 5Department of Neurology, Leiden University Medical Centre, 2300RC Leiden, The Netherlands, and 6Institute of Neurology, University College London, Queen Square, London, UK.
Poster 10
Degree of Disability Is Predictive of Physical but not Mental Health Quality of Life in Huntington’s Disease.
B. Robottom,1 K. Anderson,1,3 J. Medalie,1 A. Gruber-Baldini,2 P. Fishman,1 S. Reich,1 W. Weiner,1 and L. Shulman.1 1University of Maryland School of Medicine, Department of Neurology, Baltimore, MD, USA. 2University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, Baltimore, MD, USA, and 3University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD, USA.
Poster 11
Striatal Volume Distinguishes Converters from Non-Converters: Findings from PREDICT-HD.
E. Aylward,1 P. Nopoulos,2 C. Ross,3 R. Pierson,2 J. Mills,2 D. Langbehn,2 V. Magnotta,2 H. Johnson,2 J. Paulsen,2 and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group.1Seattle Children’s Research Institute, Seattle, WA, USA, 2University of Iowa, Iowa City, Iowa, USA, and 3Johns Hopkins University, Baltimore, MD, USA.
Poster 12
Self-efficacy in Health Behaviors: Is there a Difference in Huntington vs. Parkinson Disease?
A. Mitchell,1 K. Anderson,2 J. Medalie3, A. Gruber-Baldini3, B. Robottom3, P. Fishman3, S. Reich3, W. Weiner,3 and L. Shulman.3 1University of Maryland, School of Medicine, Department of Pediatrics, Division of Human Genetics, Baltimore, MD, USA, 2University of Maryland, Department of Neurology & Department of Psychiatry, Baltimore, MD, USA, and 3University of Maryland, Department of Neurology, Baltimore, MD, USA.
Poster 13
Huntington's Disease Disrupts Motor Control Mechanisms that Rely on Internal Models.
J.C. Cortes, A. Dahmubed, K. Marder, J. Krakauer, and P. Mazzoni. Columbia University, New York, NY, USA.
Poster 14
Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotrophic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD).
D. Russell, D. Jennings, G. Tamagnan, J. Seibyl, A. Koren, G. Zubal, and K. Marek. The Institute for Neurodegenerative Disorders and Molecular NeuroImaging, New Haven, CT, USA.
Poster 15
A Successful Short and Long Term Recruiting Strategy for Huntington Clinical Trials: A Community Effort.
L. Goodman,1 R. Carnes,2 J. Giuliano,3 and L. Vetter.4 1HD Drug Works, Seattle, WA, USA. 2Olympia Support Group, Olympia, WA, USA, 3CHDI Foundation, Princeton, NJ, USA, and 4Huntington’s Disease Society of America, NY, NY, USA.
Poster 16
Genetic Approach to Huntington’s Disease Therapeutics.
M. MacDonald, J. Min Lee, I. Sik Seong, E. Fossale, M.A. Anderson, V. Wheeler, and J. Gusella. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Poster 17
Metabolic Profiling in Non-Human Primate Model of Huntington’s Disease Reveals Early Disruptions in Tryptophan Metabolism.
J. Johnson, T. Yu, D. Jones, and A. Chan. Emory University, Atlanta, GA, USA.
Late-Breaking Abstracts
Poster 18
Lack of Awareness of Motor and Cognitive Phenoconversion in Huntington’s Disease.
K. Richardson,1 E. McCusker,1 C. Loy,1 J. Griffith,1 J. Mills,2 J.S. Paulsen,2 and the Predict-HD Investigators of the Huntington Study Group. 1Westmead Hospital, Sydney NSW, Australia and 2University of Iowa, Iowa City IA, USA.
Poster 19
Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington’s Disease Rating Scale (UHDRS) Motor Score.
S. Waters, 1 J. Tedroff, 2 and K. Kieburtz. 3 1NeuroSearch Sweden AB, Göteborg, Sweden, 2NeuroSearch Sweden AB, Stockholm, Sweden, and 3University of Rochester, Rochester, NY, USA.
Poster 20
Pridopidine (ACR16) in Huntington’s Disease: An Update on the MermaiHD and HART Studies.
J. Tedroff,1 P. Lindskov Krogh,2 A. Buusman,2 and Å. Rembratt.2 1NeuroSearch Sweden AB, Stockholm, Sweden and 2NeuroSearch A/S, Ballerup, Denmark.
Poster 21
EURO-HDB – The First Large, Comprehensive European Study on the Burden of Huntington’s Disease.
J. Dorey,1 J. Tedroff,2 M. Lamure,3 and M. Toumi.3 1Creativ Ceutical, Paris, France, 2NeuroSearch Sweden AB, Stockholm, Sweden, and 3University Claude Bernard Lyon 1, Villeurbanne, France.
Poster 22
The Huntington Self-Assessment Instrument (HSAI): A Comprehensive and Specific Tool to Measure the Burden of Huntington’s Disease.
J. Tedroff,1 J. Dorey,2 M. Lamure,3 J.-M. Graf von der Schulenburg,4 and M. Toumi.3 1NeuroSearch Sweden AB, Stockholm, Sweden, 2Creativ Ceutical, Paris, France, 3University Claude Bernard Lyon 1, Villeurbanne, France, and 4Institut für Versicherungsbetriebslehre, Leibniz Universität Hannover, Königsworther Platz 1, Hannover, Germany.
Poster 23
Pharmacology of the Dopaminergic Stabilizer Pridopidine (ACR16).
S. Waters,1 F. Pettersson,1 T. Dyhring,2 C. Sonesson,1 J. Tedroff,3 N. Waters,1 and H. Pontén.1 1NeuroSearch Sweden AB, Gothenburg, Sweden, 2NeuroSearch A/S, Ballerup, Denmark, and 3NeuroSearch Sweden AB, Stockholm, Sweden.
Poster 24
Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington’s Disease by Gene Status: The Prospective Huntington’s Disease Observational At-Risk Study (PHAROS).
Huntington Study Group PHAROS Investigators (K. Biglan, corresponding author). University or Rochester, Rochester, NY, USA.
Poster 25
Word Reading Compared to Demographics-Based Estimates of Premorbid IQ in Early Huntington Disease.
W. Adams, J. Byars, J. O’Rourke, A. Flynn, J. Fiedorowicz, K. Duff, A. Leserman, P. Nopoulos, and L. Beglinger. University of Iowa, Iowa City, IA, USA.
Poster 26
Characterizing Psychomotor Declines in Prodromal Huntington Disease with the Trail Making Test.
J. O’Rourke,1 L. Beglinger,1 J. Mills,1 M. Smith,1 J. Stout,2 S. Queller,3 S. Rao,4 J. Zimbelman,4 and J. Paulsen.1 1University of Iowa, Iowa City, IA, USA., 2Monash University, Melbourne, Australia, 3Indiana University, Bloomington, Indiana, USA, and 4Cleveland Clinic, Cleveland, Ohio, USA.
Poster 27
Delphi Process for the Development of Treatment Guidelines for Behavioral Symptoms and Chorea in Huntington’s Disease.
E. van Duijn,1 M. Groves,2 D. Craufurd,3 K. Anderson,4 M. Guttman,5 E. Wexler,6 S. Perlman,7 J.-M. Burgunder,8 A. Rosenblatt,9 D. van Kammen,10 J. Giuliano,10 and L. Goodman11. 1Leiden University Medical Center, Psychiatry, Leiden, The Netherlands, 2Beth Israel Medical Center, Psychiatry, NY, NY, USA, 3Manchester University, Psychiatry, Manchester, UK , 4University of Maryland, Dept of Neurology and Dept of Psychiatry, Baltimore, Maryland, USA, 5The Centre for Movement Disorders, Markum, Ontario, Canada, 6Dept. of Psychiatry & Biobehavioral Sciences, UCLA Center for Neurobehavioral Genetics, Los Angeles, CA, USA, 7University of California, Los Angeles, Los Angeles CA, USA, 8Neurologische Klinik und Poliklinik, Universitätsspital Bern, Bern, Switzerland, 9Dept. Of Psychiatry, Johns Hopkins University, Baltimore, MD USA, 10Cure Huntington’s Disease Initiative (CHDI), Princeton, NJ, USA, and 11HD Drug Works, Lake Forest Park, WA, USA.
Poster 28
Multivariate Clinical Predictors of Huntington Disease (HD): Prospective Results from the PREDICT-HD Study.
D. Langbehn, J. Paulsen and the PREDICT-HD Investigators of the Huntington Study Group. University of Iowa. Iowa City, Iowa, USA.